Home > Cardiology > AHA 2021 > Vascular Diseases: PVD > Rivaroxaban regimen beneficial after revascularisation for claudication

Rivaroxaban regimen beneficial after revascularisation for claudication

Presented By
Prof. Marc Bonaca, University of Colorado, USA
Conference
AHA 2021
Trial
VOYAGER PAD
A regimen of rivaroxaban plus low-dose aspirin showed consistent benefits for patients with claudication who underwent lower-extremity revascularisation (LER) and patients with critical limb-threatening ischaemia (CLTI) that were subjected to LER. Thus, rivaroxaban plus aspirin is a valid adjunctive therapy option for patients with claudication after LER [1]. The VOYAGER PAD trial (NCT02504216) showed a significant reduction of major cardiovascular events in patients with CLTI or claudication after LER who were treated with rivaroxaban compared with placebo (HR 0.86; P=0.0086) [2]. The current subanalysis analysed the consistency of these results across the different patient conditions (i.e. claudication or CLTI). Furthermore, the study described haemodynamic and patient-reported outcomes, and the risk profile of major adverse events in patients with claudication a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on